The drug-coated balloons market size has grown rapidly in recent years. It will grow from $1.24 billion in 2025 to $1.43 billion in 2026 at a compound annual growth rate (CAGR) of 15.5%. The growth in the historic period can be attributed to increasing prevalence of cardiovascular diseases, expansion of interventional cardiology procedures, early adoption of paclitaxel-coated balloons, growing demand for restenosis prevention, advancements in angioplasty techniques.
The drug-coated balloons market size is expected to see rapid growth in the next few years. It will grow to $2.55 billion in 2030 at a compound annual growth rate (CAGR) of 15.6%. The growth in the forecast period can be attributed to increasing use of dcb therapies in coronary applications, rising adoption of next-generation coating technologies, expansion of catheter-based interventions, growing investments in vascular innovation, increasing preference for stent-free treatment options. Major trends in the forecast period include increasing adoption of sirolimus-coated balloons, rising use of dcbs in peripheral artery disease, growing preference for minimally invasive vascular treatments, expansion of advanced drug-coating technologies, enhanced focus on improved drug delivery efficiency.
The increasing prevalence of coronary artery disease (CAD) is projected to drive the growth of the drug-coated balloons market in the future. CAD is a medical condition characterized by the narrowing or blockage of the coronary arteries that supply blood to the heart muscle, often leading to heart attacks. Drug-coated balloons are medical devices used to treat coronary artery disease, releasing medication into the artery during the procedure to help prevent restenosis, which is the re-narrowing of the artery following angioplasty. For instance, a study published in the Journal of the American College of Cardiology in August 2022 indicated that all four cardiovascular risk factors are expected to rise among the general U.S. population from 2025 to 2060. Diabetes is projected to see the most significant increase at 39.3%, followed by dyslipidemia at 27.6%, hypertension at 25.1%, and obesity at 18.3%. Additionally, the researchers found that rates of heart failure (33.4%) and ischemic heart disease (30.7%) are expected to experience the largest increases, along with heart attacks (16.9%) and strokes (33.8%). Consequently, the rise in coronary artery disease prevalence is anticipated to boost the drug-coated balloon market.
Leading companies in the drug-coated balloon sector are dedicated to advancing their technologies, including paclitaxel-coated balloon catheters, to improve treatment efficacy for conditions such as coronary in-stent restenosis. These advancements aim to enhance patient outcomes and minimize the risk of complications associated with traditional therapies. Paclitaxel-coated balloon catheters are specialized devices that release the drug paclitaxel into the artery wall upon inflation, helping to prevent re-narrowing after angioplasty. For instance, in March 2024, Boston Scientific Corporation, a U.S.-based medical device manufacturer, received approval from the U.S. Food and Drug Administration (FDA) for its AGENT™ Drug-Coated Balloon (DCB). This device is designed specifically for treating coronary in-stent restenosis (ISR) in patients with coronary artery disease, which occurs when a previously stented blood vessel becomes obstructed or narrowed due to plaque or scar tissue.
In October 2023, Cordis US Corp, a U.S.-based manufacturer of interventional cardiovascular technologies, acquired Med Alliance SA for an undisclosed amount, reported at approximately $1.1 billion, with total consideration of up to $1.135 billion. Through this acquisition, Cordis aims to incorporate Med Alliance’s SELUTION SLR™ sirolimus micro-reservoir drug-coated balloon into its coronary and peripheral portfolios to accelerate market access, expand clinical development, and offer broader treatment options for patients with coronary and peripheral vascular disease. Med Alliance SA, based in Switzerland, specializes in drug-coated balloons.
Major companies operating in the drug-coated balloons market are Boston Scientific Corporation, Medtronic plc, Abbott Laboratories, B. Braun Melsungen AG, Terumo Corporation, Biotronik SE & Co. KG, Biosensors International Group Ltd, Concept Medical Inc., Acotec Scientific AG, Cardionovum GmbH, MedAlliance SA, iVascular SLU, Minvasys SAS, QT Vascular Ltd, Hexacath SAS, Cordis Corporation, MicroPort Scientific Corporation, Endocor GmbH, Orchestra BioMed Inc., Lepu Medical Technology Co. Ltd, Balton Sp. z o.o., BrosMed Medical Co. Ltd.
North America was the largest region in the global drug-coated balloons market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the drug-coated balloons market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the drug-coated balloons market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are influencing the drug-coated balloons market by increasing costs of imported catheter materials, specialty polymers, drug-coating compounds, and precision manufacturing equipment. Hospitals and cardiac catheterization labs in North America and Europe are most affected due to reliance on imported high-value components, while Asia-Pacific faces cost pressures on device exports. These tariffs are raising procedure costs and slowing device adoption. At the same time, they are encouraging local manufacturing, regional R&D investments, and development of cost-optimized drug-coated balloon technologies.
The drug-coated balloons market research report is one of a series of new reports that provides drug-coated balloons market statistics, including drug-coated balloons industry global market size, regional shares, competitors with a drug-coated balloons market share, detailed drug-coated balloons market segments, market trends and opportunities, and any further data you may need to thrive in the drug-coated balloons industry. This drug-coated balloons market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
A drug-coated balloon (DCB) is a medical device employed in the intervention of narrowed or obstructed blood vessels, particularly in interventional cardiology and interventional radiology. Its design facilitates the direct delivery of medication to the site of vascular disease while concurrently performing angioplasty.
The primary categories of products encompassed within drug-coated balloons include those tailored for peripheral artery disease, coronary artery disease, and other indications. Drug-coated balloons (DCBs) for peripheral artery disease are a specific type of medical device utilized in addressing peripheral artery disease (PAD). PAD is characterized by the narrowing or blockage of blood vessels outside the heart or in the lower extremities. Various drug types, such as paclitaxel and sirolimus, are employed, and the end-users encompass hospitals, cardiac catheterization labs, and ambulatory surgical centers.
The drug-coated balloons market consists of sales of everolimus and zotarolimus drug-coated balloons. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
The drug-coated balloons market size is expected to see rapid growth in the next few years. It will grow to $2.55 billion in 2030 at a compound annual growth rate (CAGR) of 15.6%. The growth in the forecast period can be attributed to increasing use of dcb therapies in coronary applications, rising adoption of next-generation coating technologies, expansion of catheter-based interventions, growing investments in vascular innovation, increasing preference for stent-free treatment options. Major trends in the forecast period include increasing adoption of sirolimus-coated balloons, rising use of dcbs in peripheral artery disease, growing preference for minimally invasive vascular treatments, expansion of advanced drug-coating technologies, enhanced focus on improved drug delivery efficiency.
The increasing prevalence of coronary artery disease (CAD) is projected to drive the growth of the drug-coated balloons market in the future. CAD is a medical condition characterized by the narrowing or blockage of the coronary arteries that supply blood to the heart muscle, often leading to heart attacks. Drug-coated balloons are medical devices used to treat coronary artery disease, releasing medication into the artery during the procedure to help prevent restenosis, which is the re-narrowing of the artery following angioplasty. For instance, a study published in the Journal of the American College of Cardiology in August 2022 indicated that all four cardiovascular risk factors are expected to rise among the general U.S. population from 2025 to 2060. Diabetes is projected to see the most significant increase at 39.3%, followed by dyslipidemia at 27.6%, hypertension at 25.1%, and obesity at 18.3%. Additionally, the researchers found that rates of heart failure (33.4%) and ischemic heart disease (30.7%) are expected to experience the largest increases, along with heart attacks (16.9%) and strokes (33.8%). Consequently, the rise in coronary artery disease prevalence is anticipated to boost the drug-coated balloon market.
Leading companies in the drug-coated balloon sector are dedicated to advancing their technologies, including paclitaxel-coated balloon catheters, to improve treatment efficacy for conditions such as coronary in-stent restenosis. These advancements aim to enhance patient outcomes and minimize the risk of complications associated with traditional therapies. Paclitaxel-coated balloon catheters are specialized devices that release the drug paclitaxel into the artery wall upon inflation, helping to prevent re-narrowing after angioplasty. For instance, in March 2024, Boston Scientific Corporation, a U.S.-based medical device manufacturer, received approval from the U.S. Food and Drug Administration (FDA) for its AGENT™ Drug-Coated Balloon (DCB). This device is designed specifically for treating coronary in-stent restenosis (ISR) in patients with coronary artery disease, which occurs when a previously stented blood vessel becomes obstructed or narrowed due to plaque or scar tissue.
In October 2023, Cordis US Corp, a U.S.-based manufacturer of interventional cardiovascular technologies, acquired Med Alliance SA for an undisclosed amount, reported at approximately $1.1 billion, with total consideration of up to $1.135 billion. Through this acquisition, Cordis aims to incorporate Med Alliance’s SELUTION SLR™ sirolimus micro-reservoir drug-coated balloon into its coronary and peripheral portfolios to accelerate market access, expand clinical development, and offer broader treatment options for patients with coronary and peripheral vascular disease. Med Alliance SA, based in Switzerland, specializes in drug-coated balloons.
Major companies operating in the drug-coated balloons market are Boston Scientific Corporation, Medtronic plc, Abbott Laboratories, B. Braun Melsungen AG, Terumo Corporation, Biotronik SE & Co. KG, Biosensors International Group Ltd, Concept Medical Inc., Acotec Scientific AG, Cardionovum GmbH, MedAlliance SA, iVascular SLU, Minvasys SAS, QT Vascular Ltd, Hexacath SAS, Cordis Corporation, MicroPort Scientific Corporation, Endocor GmbH, Orchestra BioMed Inc., Lepu Medical Technology Co. Ltd, Balton Sp. z o.o., BrosMed Medical Co. Ltd.
North America was the largest region in the global drug-coated balloons market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the drug-coated balloons market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the drug-coated balloons market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are influencing the drug-coated balloons market by increasing costs of imported catheter materials, specialty polymers, drug-coating compounds, and precision manufacturing equipment. Hospitals and cardiac catheterization labs in North America and Europe are most affected due to reliance on imported high-value components, while Asia-Pacific faces cost pressures on device exports. These tariffs are raising procedure costs and slowing device adoption. At the same time, they are encouraging local manufacturing, regional R&D investments, and development of cost-optimized drug-coated balloon technologies.
The drug-coated balloons market research report is one of a series of new reports that provides drug-coated balloons market statistics, including drug-coated balloons industry global market size, regional shares, competitors with a drug-coated balloons market share, detailed drug-coated balloons market segments, market trends and opportunities, and any further data you may need to thrive in the drug-coated balloons industry. This drug-coated balloons market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
A drug-coated balloon (DCB) is a medical device employed in the intervention of narrowed or obstructed blood vessels, particularly in interventional cardiology and interventional radiology. Its design facilitates the direct delivery of medication to the site of vascular disease while concurrently performing angioplasty.
The primary categories of products encompassed within drug-coated balloons include those tailored for peripheral artery disease, coronary artery disease, and other indications. Drug-coated balloons (DCBs) for peripheral artery disease are a specific type of medical device utilized in addressing peripheral artery disease (PAD). PAD is characterized by the narrowing or blockage of blood vessels outside the heart or in the lower extremities. Various drug types, such as paclitaxel and sirolimus, are employed, and the end-users encompass hospitals, cardiac catheterization labs, and ambulatory surgical centers.
The drug-coated balloons market consists of sales of everolimus and zotarolimus drug-coated balloons. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary
2. Drug-Coated Balloons Market Characteristics
3. Drug-Coated Balloons Market Supply Chain Analysis
4. Global Drug-Coated Balloons Market Trends and Strategies
5. Drug-Coated Balloons Market Analysis of End Use Industries
7. Global Drug-Coated Balloons Strategic Analysis Framework, Current Market Size, Market Comparisons and Growth Rate Analysis
8. Global Drug-Coated Balloons Total Addressable Market (TAM) Analysis for the Market
9. Drug-Coated Balloons Market Segmentation
10. Drug-Coated Balloons Market Regional and Country Analysis
11. Asia-Pacific Drug-Coated Balloons Market
12. China Drug-Coated Balloons Market
13. India Drug-Coated Balloons Market
14. Japan Drug-Coated Balloons Market
15. Australia Drug-Coated Balloons Market
16. Indonesia Drug-Coated Balloons Market
17. South Korea Drug-Coated Balloons Market
18. Taiwan Drug-Coated Balloons Market
19. South East Asia Drug-Coated Balloons Market
20. Western Europe Drug-Coated Balloons Market
21. UK Drug-Coated Balloons Market
22. Germany Drug-Coated Balloons Market
23. France Drug-Coated Balloons Market
24. Italy Drug-Coated Balloons Market
25. Spain Drug-Coated Balloons Market
26. Eastern Europe Drug-Coated Balloons Market
27. Russia Drug-Coated Balloons Market
28. North America Drug-Coated Balloons Market
29. USA Drug-Coated Balloons Market
30. Canada Drug-Coated Balloons Market
31. South America Drug-Coated Balloons Market
32. Brazil Drug-Coated Balloons Market
33. Middle East Drug-Coated Balloons Market
34. Africa Drug-Coated Balloons Market
36. Drug-Coated Balloons Market Competitive Landscape and Company Profiles
37. Drug-Coated Balloons Market Other Major and Innovative Companies
40. Drug-Coated Balloons Market High Potential Countries, Segments and Strategies
41. Appendix
List of Tables
Executive Summary
Drug-Coated Balloons Market Global Report 2026 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses drug-coated balloons market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on end user analysis.
- Benchmark performance against key competitors based on market share, innovation, and brand strength.
- Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for drug-coated balloons? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The drug-coated balloons market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
- The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
- The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
- The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
- The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Report Scope
Markets Covered:
1) By Product: Drug-Coated Balloons For Peripheral Artery Disease; Drug-Coated Balloons For Coronary Artery Disease2) By Drug Type: Paclitaxel; Sirolimus
3) By End User: Hospitals; Cardiac Catheterization Labs; Ambulatory Surgical Centers
Subsegments:
1) By Drug-Coated Balloons For Peripheral Artery Disease: Paclitaxel-Coated Balloons; Sirolimus-Coated Balloons2) By Drug-Coated Balloons For Coronary Artery Disease: Paclitaxel-Coated Balloons; Sirolimus-Coated Balloons
Companies Mentioned: Boston Scientific Corporation; Medtronic plc; Abbott Laboratories; B. Braun Melsungen AG; Terumo Corporation; Biotronik SE & Co. KG; Biosensors International Group Ltd; Concept Medical Inc.; Acotec Scientific AG; Cardionovum GmbH; MedAlliance SA; iVascular SLU; Minvasys SAS; QT Vascular Ltd; Hexacath SAS; Cordis Corporation; MicroPort Scientific Corporation; Endocor GmbH; Orchestra BioMed Inc.; Lepu Medical Technology Co. Ltd; Balton Sp. z o.o.; BrosMed Medical Co. Ltd
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report + Excel Dashboard
Added Benefits:
- Bi-Annual Data Update
- Customisation
- Expert Consultant Support
Companies Mentioned
The companies featured in this Drug-Coated Balloons market report include:- Boston Scientific Corporation
- Medtronic plc
- Abbott Laboratories
- B. Braun Melsungen AG
- Terumo Corporation
- Biotronik SE & Co. KG
- Biosensors International Group Ltd
- Concept Medical Inc.
- Acotec Scientific AG
- Cardionovum GmbH
- MedAlliance SA
- iVascular SLU
- Minvasys SAS
- QT Vascular Ltd
- Hexacath SAS
- Cordis Corporation
- MicroPort Scientific Corporation
- Endocor GmbH
- Orchestra BioMed Inc.
- Lepu Medical Technology Co. Ltd
- Balton Sp. z o.o.
- BrosMed Medical Co. Ltd
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 250 |
| Published | February 2026 |
| Forecast Period | 2026 - 2030 |
| Estimated Market Value ( USD | $ 1.43 Billion |
| Forecasted Market Value ( USD | $ 2.55 Billion |
| Compound Annual Growth Rate | 15.6% |
| Regions Covered | Global |
| No. of Companies Mentioned | 23 |
